The latest price target for Repligen (NASDAQ:RGEN) was reported by Wolfe Research on November 14, 2024. The analyst firm set a price target for $0.00 expecting RGEN to fall to within 12 months (a possible -100.00% downside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Repligen (NASDAQ:RGEN) was provided by Wolfe Research, and Repligen initiated their peer perform rating.

The last upgrade for Repligen Corp happened on June 26, 2024 when Deutsche Bank raised their price target to $155. Deutsche Bank previously had a hold for Repligen Corp.

The last downgrade for Repligen Corp happened on December 4, 2023 when Benchmark changed their price target from N/A to N/A for Repligen Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Repligen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Repligen was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Repligen (RGEN) rating was a initiated with a price target of $0.00 to $0.00. The current price Repligen (RGEN) is trading at is $139.39, which is out of the analyst’s predicted range.